Regeneron Pharmaceuticals (STU:RGO) Total Equity: €27,181 Mil (As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
89 GF Score
Price €568.10
GF Value €788.85
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Total Equity?

Regeneron Pharmaceuticals STU:RGO -0.19% 89 Total Equity is €27,181 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 89/100 and a GF Value™ of €788.85 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was €27,181 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Regeneron Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Total Equity Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,610.39 21,394.82 23,817.33 28,032.69 26,693.39

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27,183.53 25,957.03 26,376.05 26,693.39 27,181.41
STU:RGO
89GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Regeneron Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=34637.13-7943.737
=26,693

Regeneron Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=35351.512-8170.098
=27,181

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €27,181 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Total Equity of €27,181 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Total Equity too high?
Regeneron Pharmaceuticals' current Total Equity is €27,181 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Total Equity compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Total Equity of €27,181 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Total Equity is €27,181 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €788.85, compared to a current price of €568.10 — trading 28% below its estimated fair value. The current Total Equity is €27,181 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Total Equity is €27,181 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €568.10 is trading 28% below its estimated GF Value™ of €788.85. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:RGO:

  • Total Equity: €27,181 Mil
  • GF Value™: €788.85 vs. price of €568.10 (28% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
89GF Score

Get the complete analysis for STU:RGO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€568.10
Price
€788.85
GF Value